References
- 1. D. Leitsch, Drug resistance in the microaerophilic parasite Giardia lamblia, Curr. Trop. Med. Rep.2 (2015) 128–135; https://doi.org/10.1007/s40475-015-0051-110.1007/s40475-015-0051-1452369426258002
- 2. B. R. Ansell, M. J. McConville, S. Y. Ma’ayeh, M. J. Dagley, R. B. Gasser, S. G. Svärd and A. R. Jex, Drug resistance in Giardia duodenalis, Biotechnol. Adv.33 (2015) 888–901; https://doi.org/10.1016/j.biotechadv.2015.04.00910.1016/j.biotechadv.2015.04.00925922317
- 3. C. B. Menezes, A. P. Frasson and T. Tasca, Trichomoniasis – are we giving the deserved attention to the most common non-viral sexually transmitted disease worldwide?, Microb. Cell3 (2016) 404–419; https://doi.org/10.15698/mic2016.09.52610.15698/mic2016.09.526535456828357378
- 4. D. Leitsch, Recent advances in the Trichomonas vaginalis field, F1000Res.5 (2016) Article ID 162 (7 pages); https://doi.org/10.12688/f1000research.7594.110.12688/f1000research.7594.1475539626918168
- 5. P. Kissinger, Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues, BMC Infect. Dis.15 (2015) Article ID 307 (8 pages); https://doi.org/10.1186/s12879-015-1055-010.1186/s12879-015-1055-0452574926242185
- 6. P. Upcroft and J. A. Upcroft, Drug targets and mechanisms of resistance in the anaerobic protozoa, Clin. Microbiol. Rev.14 (2001) 150–164; https://doi.org/10.1128/CMR.14.1.150-164.200110.1128/CMR.14.1.150-164.20018896711148007
- 7. P. A. Cano, A. Islas-Jácome, J. González-Marrero, L. Yépez-Mulia, F. Calzada and R. Gámez-Montaño, Synthesis of 3-tetrazolylmethyl-4H-chromen-4-ones via Ugi-azide and biological evaluation against Entamoeba histolytica, Giardia lamblia and Trichomona vaginalis, Bioorg. Med. Chem.22 (2014) 1370–1376; https://doi.org/10.1016/j.bmc.2013.12.06910.1016/j.bmc.2013.12.06924468633
- 8. S. Chaturvedi, M. Y. Malik, M. Rashid, S. Singh, V. Tiwari, P. Gupta, S. Shukla, S. Singh and M. Wahajuddin, Mechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: possible role of nitric oxide isoforms and inflammatory cytokines, Neurotoxicology79 (2020) 1–10; https://doi.org/10.1016/j.neuro.2020.03.00210.1016/j.neuro.2020.03.00232151614
- 9. J. Jampilek, Recent advances in design of potential quinoxaline anti-infectives, Curr. Med. Chem.21 (2014) 4347–4373; https://doi.org/10.2174/092986732166614101119482510.2174/092986732166614101119482525312209
- 10. I. Balderas-Renteria, P. Gonzalez-Barranco, A. Garcia, B. K. Banik and G. Rivera, Anticancer drug design using scaffolds of β-lactams, sulfonamides, quinoline, quinoxaline and natural products. Drugs advances in clinical trials, Curr. Med. Chem.19 (2012) 4377–4398; https://doi.org/10.2174/09298671280325159310.2174/09298671280325159322709002
- 11. N. B. Patel, J. N. Patel, A. C. Purohit, V. M. Patel, D. P. Rajani, R. Moo-Puc, J. C. Lopez-Cedillo, B. Nogueda-Torres and G. Rivera, In vitro and in vivo assessment of newer quinoxaline-oxadiazole hybrids as antimicrobial and antiprotozoal agents, Int. J. Antimicrob. Agents50 (2017) 413–418; https://doi.org/10.1016/j.ijantimicag.2017.04.01610.1016/j.ijantimicag.2017.04.01628687457
- 12. G. Cheng, W. Sa, C. Cao, L. Guo, H. Hao, Z. Liu, X. Wang and Z. Yuan, Quinoxaline 1,4-di-N-oxides: Biological activities and mechanisms of actions, Front. Pharmacol.7 (2016) Article ID 64 (21 pages); https://doi.org/10.3389/fphar.2016.0006410.3389/fphar.2016.00064480018627047380
- 13. R. El Aissi, J. Liu, S. Besse, D. Canitrot, O. Chavignon, J. M. Chezal, E. Miot-Noirault and E. Moreau, Synthesis and biological evaluation of new quinoxaline derivatives of ICF01012 as melanoma-targeting probes, ACS Med. Chem. Lett.5 (2014) 468–473; https://doi.org/10.1021/ml400468x10.1021/ml400468x402760924900863
- 14. J. C. Villalobos-Rocha, L. Sánchez-Torres, B. Nogueda-Torres, A. Segura-Cabrera, C. A. García-Pérez, V. Bocanegra-García, I. Palos, A. Monge and G. Rivera, Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives, Parasitol. Res.113 (2014) 2027–2035; https://doi.org/10.1007/s00436-014-3850-810.1007/s00436-014-3850-824691716
- 15. K. F. Chacón-Vargas, S. Andrade-Ochoa, B. Nogueda-Torres, D. C. Juárez-Ramírez, E. E. Lara-Ramírez, R. Mondragón-Flores, A. Monge and G. Rivera, L. E. Sánchez-Torres, Isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives induce regulated necrosis-like cell death on Leish-mania (Leishmania) mexicana, Parasitol. Res.117 (2018) 45–58; https://doi.org/10.1007/s00436-017-5635-310.1007/s00436-017-5635-329159705
- 16. M. Quiliano, A. Pabón, G. Ramirez-Calderon, C. Barea, E. Deharo, S. Galiano and I. Aldana, New hydrazine and hydrazide quinoxaline 1,4-di-N-oxide derivatives: In silico ADMET, antiplasmo-dial and antileishmanial activity. Bioorg. Med. Chem. Lett.27 (2017) 1820–1825; https://doi.org/10.1016/j.bmcl.2017.02.04910.1016/j.bmcl.2017.02.04928291694
- 17. B. E. Duque-Montaño, L. C. Gómez-Caro, M. Sanchez-Sanchez, A. Monge, E. Hernández-Baltazar, G. Rivera and O. Torres-Angeles, Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba histolytica, Bioorg. Med. Chem.21 (2013) 4550–4558; https://doi.org/10.1016/j.bmc.2013.05.03610.1016/j.bmc.2013.05.03623787289
- 18. L. C. Gómez-Caro, M. Sánchez-Sánchez, V. Bocanegra-García, A. Monge and G. Rivera, Synthesis of quinoxaline 1,4-di-N-oxide derivatives on solid support using room temperature and microwave-assisted solvent-free procedures, Quim. Nova34 (2011) 1147–1151; https://doi.org/10.1590/S0100-4042201100070000810.1590/S0100-40422011000700008
- 19. E. Hernández-Núñez, H. Tlahuext, R. Moo-Puc, H. Torres-Gómez, R. Reyes-Martínez, R Cedillo-Rivera, C. Nava-Zuazo and G. Navarrete-Vazquez, Synthesis and in vitro trichomonicidal, giardicidal and amebicidal activity of N-acetamide(sulfonamide)-2-methyl-4-nitro-1H-imidazoles, Eur. J. Med. Chem.44 (2009) 2975–2984; https://doi.org/10.1016/j.ejmech.2009.01.00510.1016/j.ejmech.2009.01.00519208443
- 20. B. R. Brooks, C. L. Brooks, A. D. Mackerell, L. Nilsson, R. J. Petrella, B. Roux, Y. Won, G. Archontis, C. Bartels, S. Boresch, A. Caflisch, L. Caves, Q. Cui, A. R. Dinner, M. Feig, S. Fischer, J. Gao, M. Hodoscek, W. Im, K. Kuczera, T. Lazaridis, J. Ma, V. Ovchinnikov, E. Paci, R. W. Pastor, C. B. Post, J. Z. Pu, M. Schaefer, B. Tidor, R. M. Venable, H. L. Woodcock, X. Wu, W. Yang, D. M. York and M. Karplus, CHARMM: The biomolecular simulation program, J. Comput. Chem.30 (2009) 1545–1614; https://doi.org/10.1002/jcc.2128710.1002/jcc.21287281066119444816
- 21. P. R. Gerber and K. Müller, MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry, J. Comput. Aided Mol. Des.9 (1995) 251–268; https://doi.org/10.1007/bf0012445610.1007/BF00124456
- 22. C. A. Del Carpio, Y. Takahashi and S.-i. Sasaki, A new approach to the automatic identification of candidates for ligand receptor sites in proteins: (I) Search for pocket regions, J. Mol. Graph.11 (1993) 23–29; https://doi.org/10.1016/0263-7855(93)85003-9
- 23. A. Miranker and M. Karplus, Functionality maps of binding sites: A multiple copy simultaneous search method, Proteins: Struct. Funct. Genet.11 (1991) 29–34; https://doi.org/10.1002/prot.3401101010.1002/prot.340110104
- 24. S. Thangapandian, S. John, Y. Lee, S. Kim and K. W. Lee, Dynamic structure-based pharmacophore model development: A new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery, Int. J. Mol. Sci.12 (2011) 9440–9462; https://doi.org/10.3390/ijms1212944010.3390/ijms12129440
- 25. A. Wadood, M. Ghufran, S. F. Hassan, H. Khan, S. S. Azam and U. Rashid, In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-D-xylulose 5-phosphate reductoisom-erase for treatment of Falciparum malaria, Pharm. Biol.55 (2017) 19–32; https://doi.org/10.1080/13880209.2016.122577810.1080/13880209.2016.1225778
- 26. A. M. Clark and P. Labute, 2D depiction of protein–ligand complexes, J. Chem. Inf. Model. 47 (2007) 1933–1944; https://doi.org/10.1021/ci700147310.1021/ci7001473
- 27. S. Lara-González, P. Estrella, C. Portillo, M. E. Cruces, P. Jiménez-Sandoval, J. Fattori, A. C. Migliorini-Figueira, M. López-Hidalgo, C. Díaz-Quezada, M. López-Castillo, C. H. Trasviña-Arenas, E. Sánchez-Sandoval, A. Gómez-Puyou, J. Ortega-López, R. Arroyo, C. G. Benítez-Cardoza and L. G. Brieba, Substrate-induced dimerization of engineered monomeric variants of triosephosphate isomerase from Trichomonas vaginalis, PLoS ONE10 (2015) e0141747; https://doi.org/10.1371/journal.pone.014174710.1371/journal.pone.0141747
- 28. P. Jiménez-Sandoval, J. L. Vique-Sanchez, M. L. Hidalgo, G. Velazquez-Juarez, C. Díaz-Quezada, L. F. Arroyo-Navarro, G. M. Morán, J. Fattori, A. J. Diaz-Salazar, E. Rudiño-Pinera, R. Sotelo-Mundo, A. C. Migliorini-Figueira, S. Lara-Gonzalez, C. G. Benítez-Cardoza and L. G. Brieba, A competent catalytic active site is necessary for substrate induced dimer assembly in triosephosphate isomerase, Biochim. Biophys. Acta – Prot. Proteom.1865 (2017) 1423–1432; https://doi.org/10.1016/j.bbapap.2017.07.01410.1016/j.bbapap.2017.07.014
- 29. G. Álvarez, J. Martínez, B. Aguirre-López, N. Cabrera, L. Pérez-Díaz, M. T. de Gómez-Puyou, A. Gómez-Puyou, R. Pérez-Montfort, B. Garat, A. Merlino, M. González and H. Cerecetto, New chemotypes as Trypanosoma cruzi triosephosphate isomerase inhibitors: a deeper insight into the mechanism of inhibition, J. Enzyme Inhib. Med. Chem.29 (2014) 198–204; https://doi.org/10.3109/14756366.2013.76541510.3109/14756366.2013.765415
- 30. A. Gómez-Puyou, E. Saavedra-Lira, I. Becker, R. A. Zubillaga, A. Rojo-Dominguez and R. Perez-Montfort, Using evolutionary changes to achieve species-specific inhibition of enzyme action — studies with triosephosphate isomerase, Chem. Biol.2 (1995) 847–855; https://doi.org/10.1016/1074-5521(95)90091-810.1016/1074-5521(95)90091-8
- 31. M. de N. C. Soeiro and S. L. Castro, Screening of potential anti-Trypanosoma cruzi candidates: In vitro and in vivo studies, Open Med. Chem. J.5 (2011) 21–30; https://doi.org/10.2174/187410450110501002110.2174/1874104501105010021310389721629508
- 32. G. Álvarez, B. Aguirre-López, J. Varela, M. Cabrera, A. Merlino, G. V. López, M. L. Lavaggi, W. Porcal, R. Di Maio, M. González, H. Cerecetto, N. Cabrera, R. Pérez-Montfort, M. Tuena de Gómez-Puyou and A. Gómez-Puyou, Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity, Eur. J. Med. Chem.45 (2010) 5767–5772; https://doi.org/10.1016/j.ejmech.2010.09.03410.1016/j.ejmech.2010.09.03420889239
- 33. C. G. Benítez-Cardoza, D. A. Fernández-Velasco and J. L. Vique-Sánchez, Triosephosphate isom-erase inhibitors as potential drugs against Clostridium perfringens, Chem. Sel.5 (2020) 2365–2370; https://doi.org/10.1002/slct.20190463210.1002/slct.201904632
- 34. J. L. Vique-Sánchez, L. A. Caro-Gómez, L. G. Brieba and C. G. Benítez-Cardoza, Developing a new drug against trichomoniasis, new inhibitory compounds of the protein triosephosphate isomerase, Parasitol. Int.76 (2020) Article ID 102086; https://doi.org/10.1016/j.parint.2020.10208610.1016/j.parint.2020.102086
- 35. A. Téllez-Valencia, S. Avila-Ríos, R. Pérez-Montfort, A. Rodríguez-Romero, M. Tuena de Gómez-Puyou, F. López-Calahorra and A. Gómez-Puyou, Highly specific inactivation of triosephosphate isomerase from Trypanosoma cruzi, Biochem. Biophys. Res. Commun.295 (2002) 958–963; https://doi.org/10.1016/s0006-291x(02)00796-910.1016/S0006-291X(02)00796-9
- 36. B. Hernández-Ochoa, G. Navarrete-Vázquez, C. Nava-Zuazo, A. Castillo-Villanueva, S. T. Méndez, A. Torres-Arroyo, S. Gómez-Manzo, J. Marcial-Quino, M. Ponce-Macotela, Y. Rufino-González, M. Martínez-Gordillo, G. Palencia-Hernández, N. Esturau-Escofet, E. Calderon-Jaimes, J. Oria-Hernández and H. Reyes-Vivas, Novel giardicidal compounds bearing proton pump inhibitor scaffold proceeding through triosephosphate isomerase inactivation, Sci. Rep.7 (2017) Article ID 7810; https://doi.org/10.1038/s41598-017-07612-y10.1038/s41598-017-07612-y555269128798383